UPDATE: Cantor Fitzgerald Reiterates Neutral On Adamas Pharmaceuticals, Lowers Target To $7 Notes 'INROADS P3 Doesn't Lead to Gocovri Label-Expansion Inroads, Yet'; Firm Sees Possible Clarity 'by mid-20'